78 studies on GHRH analog class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The premature termination of this 10-year observational study means that crucial long-term safety data for Tesamorelin in HIV-associated abdominal lipohypertrophy remains largely uncollected. This is significant becau…
The early termination of this study represents a missed opportunity to explore a potential therapeutic avenue for COPD-related muscle wasting, a condition with significant unmet medical needs. Tesamorelin, a synthetic…
Peripheral nerve injuries often result in debilitating long-term deficits, making effective therapeutic interventions critically important. If Tesamorelin proves successful in this trial, it could represent a novel ph…
The successful outcome of this trial could represent a significant advancement in managing HIV-associated neurocognitive disorders (HAND), which are a growing concern in the aging HIV population. If tesamorelin proves…
This analysis provides strong evidence that tesamorelin can be broadly considered for treating excess visceral adipose tissue in people with HIV, irrespective of the presence of dorsocervical fat. This simplifies clin…
These findings underscore the critical need for continued research into HIV's impact on the central nervous system, even in the era of effective ART, and highlight the multifaceted nature of neuropsychiatric complicat…
The termination of this Phase 4 clinical trial means a critical knowledge gap remains regarding the long-term ocular safety of tesamorelin in HIV-infected patients with diabetes. Understanding the potential risks or b…
The termination of this long-running study highlights the significant challenges inherent in conducting extensive, multi-year clinical research, particularly in broad observational contexts like endocrine diseases. Wh…
Understanding the precise role of GHRH (a hormone that stimulates GH release) in acromegaly is crucial for developing more targeted therapies. If endogenous GHRH significantly contributes to GH hypersecretion, then GH…
If GHRH were found to be effective, this research could pave the way for a novel therapeutic strategy to address age-related sleep disturbances, a widespread issue affecting millions. Successfully augmenting the GH-IG…
The premature termination of this study means a potential avenue for addressing age-related decline in muscle, bone, and fat health through GHRH remains unexplored by this particular trial. If successful, GHRH could h…
This research is critical for optimizing IVF protocols for a challenging patient population with diminished ovarian reserve, who often have lower success rates with conventional treatments. If the long Clomid protocol…
The premature termination of this study means a significant opportunity was missed to explore a potential therapeutic avenue for age-related decline. Given the widespread impact of low GH levels on muscle mass, bone d…
The intent behind this study highlights a critical challenge in endocrinology: the potential for significant inter-assay variability to compromise the accurate diagnosis and management of Growth Hormone (GH) disorders…
Targeting growth hormone pathways with GHRH offers a promising therapeutic strategy for managing abdominal obesity and its associated metabolic risks. If successful, this approach could provide a novel, physiological …
Understanding the sexually dimorphic nature of GH responses to GHRH could profoundly impact the diagnosis and management of Growth Hormone Deficiency. If confirmed, these findings could lead to the development of sex-…
This foundational Phase 1 study is critical because it provides essential data on how Tesamorelin behaves in HIV positive patients, a population with unique metabolic considerations. The successful characterization of…
The potential for Tesamorelin to augment exercise benefits in HIV-positive individuals is highly significant. If successful, this intervention could offer a novel and more effective strategy to combat frailty and phys…
Understanding Tesamorelin's short-term effects in healthy individuals is crucial for broadening its potential therapeutic applications beyond HIV-associated lipodystrophy. If Tesamorelin can safely enhance GH secretio…
The investigation into TH9507, a growth hormone-releasing factor (GRF) analogue, represents an important step in exploring novel therapeutic strategies for Type 2 Diabetes. GRF plays a role in metabolic regulation, an…
Understanding how growth hormone and growth hormone-releasing hormone impact GH secretion and glucose metabolism in HIV-infected patients is profoundly important for managing HIV lipodystrophy and its associated metab…
If the GHRH + Arginine test proves to have high specificity and sensitivity comparable to the ITT, it could represent a significant advancement in diagnosing AGHD. The ITT carries inherent risks due to induced hypogly…
The termination of this study represents a missed opportunity to gain crucial insights into the complex interplay between free fatty acids, obesity, and growth hormone secretion in a vulnerable pediatric population. H…
The withdrawal of this study highlights a persistent gap in research for effective treatments for TBI-related insomnia, a condition that significantly impacts the quality of life for service members and veterans. Had …
This Phase 1 study is crucial for establishing the foundational safety and preliminary efficacy signals for VRS-317, a potential long-acting treatment for Growth Hormone Deficiency. If successful in maintaining IGF-I …
The successful development of an oral growth hormone secretagogue like AEZS-130 for diagnostic purposes would represent a significant advancement in the management of Adult Growth Hormone Deficiency (AGHD). Such a tes…
The potential of TH9507 to selectively reduce visceral adipose tissue (VAT) in HIV patients with lipodystrophy is highly significant, as this fat accumulation is strongly linked to serious metabolic complications like…
For women struggling with poor ovarian response (POR), finding effective pre-treatment strategies is paramount to improving the success rates of IVF/ICSI and alleviating the significant emotional and financial burden …
If Growth Hormone Releasing Hormone (GHRH) were to demonstrate positive effects on cognitive function in Mild Cognitive Impairment (MCI), it would offer a novel and promising therapeutic strategy for a condition with …
**Clinicians and biohackers using sermorelin or GHRP-2** should recognize that abdominal fat is the dominant suppressor of combined secretagogue synergy — not simply age or low testosterone. **Reducing AVF before or a…
These findings are significant as they identify GHRH as a trophic hormone for bronchial neuroendocrine tumors, meaning it actively promotes their growth and activity. This discovery suggests that GHRH receptors could …
**GHRH antagonists such as MZ-5-156 may have therapeutic utility not only as antiproliferatives but as suppressors of iNOS-driven nitrosative and oxidative stress in lung cancer**, a dual mechanism that broadens their…
This review underscores that peptide-based therapies represent a crucial and evolving frontier in the management of advanced prostate cancer, offering targeted mechanisms to combat disease progression. The insights ga…
This research suggests that GHRH agonists like sermorelin and its more potent analogs could be a powerful therapeutic tool for improving recovery after a heart attack. For biohackers or clinicians exploring regenerati…
This study provides compelling evidence in a large animal model that GHRH agonists like the Sermorelin analog MR-409 can directly target the heart to promote structural repair after a heart attack. The significant red…
These findings suggest that GHRH agonists like sermorelin or its analogs could be a promising therapeutic strategy for the early stages of diabetic retinopathy. By targeting antioxidant and anti-inflammatory pathways,…
These findings suggest that GHRH analogs like sermorelin may have beneficial effects on mood beyond their established roles, potentially by directly modulating neuroinflammation and monoamine neurotransmitter systems …
This research identifies the `GHRH-R/JAK2/STAT3` signaling axis as a key driver of acute anterior uveitis, establishing a new and specific therapeutic target. For clinicians and researchers, this suggests that drugs t…